Guardant Health Q2 Adj EPS $(0.82) Beats $(1.18) Estimate, Sales $137.15M Beat $129.41M Estimate
Portfolio Pulse from bharat@benzinga.com
Guardant Health (NASDAQ:GH) reported Q2 losses of $(0.82) per share, beating the analyst consensus estimate of $(1.18) by 30.51%. This is an 18% increase over losses from the same period last year. The company also reported quarterly sales of $137.15 million, beating the analyst consensus estimate of $129.41 million by 5.98%. This is a 25.66% increase over sales from the same period last year.
August 04, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Q2 results beat estimates with lower than expected losses and higher sales. This could positively impact the stock in the short term.
Guardant Health reported better than expected Q2 results, with lower losses and higher sales than estimated. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100